Pharmaceuticals Search Engine [selected websites]


Wednesday, July 4, 2012

Omron Launches Sleep Monitor With ResMed Technology

SAN DIEGO, May 23, 2012 - The Omron Sleep Design HSL-101 offers wireless sleep monitoring and connection to Wellness Link - ResMed Inc. (NYSE:RMD) announced the launch of the first product in Japan using technology from its recently acquired company, BiancaMed. The product, launched by BiancaMed partner Omron Healthcare, is a new wireless sleep monitoring device. The Omron Sleep Design HSL-101 is part of a new strategy by Omron, named "All for Healthcare."

How Omron Sleep Design Works

The device uses ResMed technology to offer wireless, non-contact sleep monitoring which in turn connects to health care support services in Japan. To use the Omron Sleep Design HSL-101, a patient places the device beside the bed. With ResMed's non-contact sensing technology, the device measures sleep throughout the night and can report key sleep quality metrics, such as sleep onset time and total sleep time. In the morning, users can generate a full report on the night's sleep with the push of a button. When the data is connected to the cloud as part of Omron's Wellness Link service, a full picture of sleep health is provided, alongside a customized summary of health tips and advice... ResMed's Press Release -

Thursday, May 17, 2012

Somaxon and CJ CheilJedang : Silenor® Collaboration in South Korea

Somaxon Pharmaceuticals
April 27, 2012 - Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) and CJ CheilJedang Corporation announced that they have entered into an exclusive collaboration under which CJ CheilJedang will commercialize Silenor® (doxepin) for the treatment of insomnia in South Korea.

CJ CheilJedang

Under the terms of the agreements, Somaxon will receive an up-front payment of US$600,000. CJ CheilJedang will be responsible for regulatory submissions for Silenor and will have the exclusive right to commercialize Silenor in South Korea. Once Silenor is approved in South Korea, Somaxon will also be eligible to receive sales-based milestone payments as well as a royalty based on net sales of Silenor in South Korea. Somaxon will also supply CJ CheilJedang's requirements for commercial quantities of Silenor in South Korea at a separate transfer price... Somaxon Pharmaceuticals' Press Release -

Thursday, April 19, 2012

Zephyr Sleep Technologies : FDA 510 (k) Clearance for MATRx™

Zephyr Sleep Technologies
March 28, 2012 - Zephyr Sleep Technologies Inc. (Zephyr) is pleased to announce that they have been granted 510(k) clearance from the U.S. Food and Drug Administration (FDA) to begin selling the MATRx medical device system.

The MATRx system will be used in sleep laboratories to identify patients that will be successful with oral appliance therapy while establishing the protrusive position of the lower mandible for effective therapy. “The MATRx system changes the way oral appliance therapy is prescribed, bringing the knowledge and expertise of both Sleep Physicians and Dentists into the therapy decision much earlier. This new technology will certainly change how things are done” says Paul Cataford, Zephyr’s President & CEO.

A MATRx study is performed in a sleep laboratory by a sleep technician in conjunction with a polysomnographic study (“PSG test”). Using this new technology Sleep Physicians will, for the first time, be able to reliably predict the effectiveness of oral appliance therapy as a treatment for obstructive sleep apnea patients. This clears the way for Sleep Physicians to confidently prescribe oral appliance therapy in advance of patients being fitted with an oral appliance. MATRx also provides Sleep Dentists with an effective target protrusive position for the lower mandible. This enables dentists to fit oral appliances with confidence in therapeutic outcome while eliminating the need for an iterative titration process that previously could take weeks.

“Understanding a patient’s airway response to mandibular protrusion is a critical component of confidently prescribing and administering oral appliance therapy. The MATRx study offers many features that are comparable to and commensurate with the traditional continuous positive airway pressure study (“CPAP study”). In fact, the two studies can now work hand-in-hand to optimize sleep apnea management.” says Zephyr’s Chief Medical Officer, Dr. John Remmers.


In Dec 2010, Zephyr signed an exclusive worldwide distribution agreement with SomnoMed Limited to market and sell this device under the name SomnoMed MATRx... [PDF] Zephyr Sleep Technologies' Press Release -

Monday, April 2, 2012

Teva : Launch of Authorized Generic of Provigil

Teva Pharmaceutical
Mar. 30, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announces the launch of the authorized generic of Provigil® (modafinil). Provigil® is marketed by Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.

This product will continue to be manufactured under the brand product's new drug application at the same facility where it is currently produced. Shipping of the product has commenced... Teva Pharmaceutical's Press Release -

Monday, March 19, 2012

CareFusion and Fisher & Paykel Healthcare Renew Exclusive Distribution Agreement for U.S. Hospital Market

Feb. 8, 2012 - CareFusion, a leading, global medical technology company, and Fisher & Paykel Healthcare, a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea, announced a three-year renewal of their longstanding agreement providing CareFusion the exclusive right to distribute Fisher & Paykel Healthcare products into the U.S. hospital market.

"For more than 25 years, we have partnered with Fisher & Paykel Healthcare to bring its portfolio of clinically differentiated respiratory solutions to U.S. hospitals," said Vivek Jain, president of the Procedural Solutions segment for CareFusion. "As we extend and strengthen our strategic relationships with proven partners like Fisher & Paykel Healthcare, our customers benefit from continued access to market-leading technologies that help improve the cost, quality and safety of patient care."

Fisher and Paykel Healthcare

Under the agreement, CareFusion, through its AirLife™ Respiratory Consumables business, will continue to serve as the exclusive U.S. distributor of Fisher & Paykel Healthcare's extensive portfolio of respiratory consumable products, including the MR850 Heated Humidification System with Evaqua™ circuit technology, AIRVO™ high flow device, Optiflow™ nasal cannula, and FlexiFit™ non-invasive interfaces... CareFusion's Press Release -

Thursday, March 8, 2012

HypnoCore : SleepRate - Sleep Monitoring Solution

February 5, 2012 - SleepRate aims to revolutionize the field of sleep, utilizing web, mobile, and consumer devices, to allow accurate and affordable access to sleep diagnostics solutions for the consumer market.

SleepRate on YouTube- HypnoCore's website -

Monday, February 6, 2012

Merck : Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia

Feb. 6, 2012 - Company Confirms Plans to File NDA for Suvorexant in 2012 -

Merck (NYSE:MRK), known as MSD outside the United States and Canada, provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if approved, will be a new mechanism for the treatment of insomnia. The two pivotal Phase III efficacy trials for suvorexant have been completed and, based on the positive results of these studies, Merck plans to file a New Drug Application (NDA) for suvorexant with the U.S. Food and Drug Administration (FDA) in 2012.

Both Phase III studies were multicenter, randomized, double-blind, placebo-controlled clinical trials that evaluated suvorexant compared to placebo in adult patients ages 18 years and older. The primary endpoint was change from baseline in subjective total sleep time and time to sleep onset, wake time after persistent sleep onset, and latency to onset of persistent sleep at one and three months. Merck plans to submit these data for presentation at major medical meetings later this year... Merck's Press Release -